Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin

被引：0
|
作者：
Ritter, W [1 ]
Ochmann, K [1 ]
Muck, W [1 ]
Kuhlmann, J [1 ]
机构：
[1] BAYER AG,CLIN PHARMACOL,D-42096 WUPPERTAL,GERMANY
来源：
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 1997年 / 355卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：477 / 477
页数：1
相关论文
共 50 条
  • [21] SYNTHESIS OF A NOVEL HMG-COA REDUCTASE INHIBITOR
    BAADER, E
    BARTMANN, W
    BECK, G
    BERGMANN, A
    JENDRALLA, H
    KESSELER, K
    WESS, G
    SCHUBERT, W
    GRANZER, E
    VONKEREKJARTO, B
    KRAUSE, R
    TETRAHEDRON LETTERS, 1988, 29 (08) : 929 - 930
  • [22] Cerivastatin - A new HMG-CoA reductase inhibitor - In combination with the antacid Maalox(R): An investigation of the safety and pharmacokinetics
    Dietrich, H
    Ritter, W
    Wingender, W
    Unger, S
    Ochmann, K
    ATHEROSCLEROSIS, 1997, 130 : 101 - 101
  • [23] HMG-CoA reductase inhibitor cerivastatin prolonged rat cardiac allograft survival by blocking intercellular signals
    Horimoto, H
    Nakai, Y
    Nakahara, K
    Nomura, Y
    Mieno, S
    Sasaki, S
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2002, 21 (04): : 440 - 445
  • [24] HMG-CoA reductase inhibitor cerivastatin inhibits interleukin-6 expression and secretion in human adipocytes
    van Harmelen, V
    Skurk, T
    Röhrig, K
    Hauner, H
    HORMONE AND METABOLIC RESEARCH, 2003, 35 (08) : 466 - 470
  • [25] Phase I study to investigate the effects of cimetidine on the pharmacokinetics of cerivastatin - A new HMG-CoA reductase inhibitor
    Frey, R
    Ritter, W
    Unger, S
    Ochmann, K
    Wingender, W
    ATHEROSCLEROSIS, 1997, 130 : 103 - 103
  • [26] Effects of cerivastatin sodium, a new HMG-CoA reductase inhibitor, on biliary lipid metabolism in patients with hypercholesterolemia
    Tazuma, S
    Yamashita, G
    Ochi, H
    Miura, H
    Kajihara, T
    Hattori, Y
    Miyake, H
    Nishioka, T
    Hyogo, H
    Sunami, Y
    Yasumiba, S
    Kajiyama, G
    CLINICAL THERAPEUTICS, 1998, 20 (03) : 477 - 485
  • [27] Efficacy and safety of cerivastatin, a novel potent HMG-CoA reductase inhibitor, in primary hypercholesterolaemia: A comparative study
    Leiter, LA
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 128 - 129
  • [28] Rhabdomyolysis following cerivastatin monotherapy - implications for therapy with HMG-CoA reductase inhibitors
    Sparing, R
    Sellhaus, B
    Noth, J
    Block, F
    NERVENARZT, 2003, 74 (02): : 167 - +
  • [29] Photoaffinity labeling of HMG-CoA reductase with azido-functionalized cerivastatin derivatives
    Ikemoto, T
    Hosoya, T
    Hiramatsu, T
    Nakanishi, M
    Hosoya, A
    Aoyama, H
    Iwata, T
    Maruyama, K
    Suzuki, M
    Endo, M
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 94 : 139P - 139P
  • [30] Cataract and HMG-CoA reductase inhibitor: a case report
    Bousquet, E
    Amar, J
    Salvador, M
    Chamontin, B
    THERAPIE, 1998, 53 (05): : 505 - 507
12345